The Maropitant Citrate API Market is expanding as veterinary healthcare providers and pharmaceutical manufacturers respond to rising demand for effective treatments for nausea and vomiting in companion animals. WiseGuyReports estimates the market at USD 200 million in 2025 and projects it to reach USD 300 million by 2035, representing a 2.6% CAGR from 2026 to 2035.
Nausea treatment represents the leading application, supported by the increasing use of maropitant citrate as an antiemetic in veterinary medicine. The application segment was valued at approximately USD 80 million in 2024 and is projected to reach USD 120 million by 2035 as awareness of animal healthcare continues to improve.
The market includes tablets, injectable formulations, and oral suspensions. Injectable products are gaining attention because veterinarians can use them when rapid therapeutic action is required, while tablets remain attractive for convenient administration and oral suspensions can support animals that have difficulty taking solid medicines.
Veterinary clinics and animal hospitals remain important end users because they provide the majority of professional treatment for nausea and vomiting. Homecare is also emerging as an opportunity as pet owners increasingly seek convenient treatment options and spend more on preventive and therapeutic animal healthcare.
North America is expected to remain the dominant regional market, supported by high pet ownership, developed veterinary infrastructure, and strong demand for animal pharmaceuticals. Asia-Pacific offers additional growth potential as pet ownership, veterinary spending, and awareness of animal health increase across emerging economies.
